• Markets
    • icon
  • Companies
PAB · ASX

Patrys Limited (ASX:PAB)

AU$0.008

 0.0 (0.0%)
ASX:Live
05/12/2023 12:00:00 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PAB Overview

PAB Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About PAB

Website

Patrys Limited

Telephone

61.3.9670.3273

Address

Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205

Description

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.

PAB Price Chart

Key Stats

Market Cap

AU$16.46M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.01 - 0.03

Trade Value (12mth)

AU$11,809.00

1 week

33.33%

1 month

-11.11%

YTD

-70.37%

1 year

-65.22%

All time high

0.619421

Key Fundamentals

EPS 3 yr Growth

36.000%

EBITDA Margin

N/A

Operating Cashflow

-$6m

Free Cash Flow Return

-57.00%

ROIC

-69.70%

Interest Coverage

N/A

Quick Ratio

10.40

Other Data

Shares on Issue (Fully Dilluted)

2056m

HALO Sector

Healthcare

Next Company Report Date

22-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PAB Announcements

Latest Announcements

Date Announcements

31 October 12

CEO Presentation to AGM 2012

×

CEO Presentation to AGM 2012

31 March 23

Updated guidance for PAT-DX1 phase 1 clinical study

×

Updated guidance for PAT-DX1 phase 1 clinical study

31 July 08

CEO presentation- 6th Annual Australian Biotechnology Summit

×

CEO presentation- 6th Annual Australian Biotechnology Summit

31 January 23

Appendix 4C - Quarterly - 31 December 2022

×

Appendix 4C - Quarterly - 31 December 2022

31 January 22

Appendix 4C - Quarterly - 31 December 2021

×

Appendix 4C - Quarterly - 31 December 2021

31 August 22

Appointment of Non-Executive Director

×

Appointment of Non-Executive Director

31 August 22

Initial Director's Interest Notice

×

Initial Director's Interest Notice

30 September 08

Annual Report to shareholders

×

Annual Report to shareholders

30 November 11

CEO`s Presentation to AGM 2011

×

CEO`s Presentation to AGM 2011

30 January 23

Patrys Receives R&D Tax Incentive Refund

×

Patrys Receives R&D Tax Incentive Refund

30 August 22

PAT-DX1 From Engineering Run Meets all Specification Tests

×

PAT-DX1 From Engineering Run Meets all Specification Tests

30 August 22

Appendix 4E and 2022 Annual Report

×

Appendix 4E and 2022 Annual Report

30 August 22

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

30 August 16

Appendix 4E and 2016 Annual Report

×

Appendix 4E and 2016 Annual Report

30 August 10

Appendix 4E and 2010 Annual Report

×

Appendix 4E and 2010 Annual Report

30 August 10

Patrys 2010 Annual Report

×

Patrys 2010 Annual Report

29 November 23

Notification of cessation of securities - PAB

×

Notification of cessation of securities - PAB

29 November 23

Change of Director's Interest Notices x2

×

Change of Director's Interest Notices x2

29 August 17

Appendix 4E and 2017 Annual Report

×

Appendix 4E and 2017 Annual Report

28 September 21

Company Overview Presentation - September 2021

×

Company Overview Presentation - September 2021

28 September 12

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

28 September 10

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

28 September 07

Annual Report to shareholders

×

Annual Report to shareholders

28 October 22

Appendix 4C - Quarterly - 30 September 2022

×

Appendix 4C - Quarterly - 30 September 2022

28 October 11

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

28 July 22

Appendix 4C - Quarterly - 30 June 2022

×

Appendix 4C - Quarterly - 30 June 2022

28 February 22

Stable Cell Line for Production of PAT-DX3 Established

×

Stable Cell Line for Production of PAT-DX3 Established

PAB Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 -40.0 2.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.4 -51.6 -6.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -4.3 -22.1 -28.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 57.9 -0.3 -50.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,617 1,961 2,055 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,617 1,961 2,055 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 -100.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 6 11 10 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -68.6 -95.0 13.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -21,127.2 -41,189.7 N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -6 -11 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -67.7 -94.2 13.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -21,303.8 -41,362.6 N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -6 -12 -10 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -5 -3 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -4 -7 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.8 -66.9 -4.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -14,774.3 -24,655.9 N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -9 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -4 2 1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 11 8 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -9 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.5 -123.7 33.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -141.1 -315.7 N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 7 8 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 13 14 8 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -7 -8 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 12 13 7 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 12 13 7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 146.9 11.5 -49.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -31.5 -48.5 -93.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -33.7 -50.5 -103.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -69.2 -89.3 -97.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -48.0 -53.2 -69.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -45.8 -68.2 -57.0 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.2 0.7 0.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -57.4 -58.2 -59.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 14.6 24.9 10.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 14.6 24.9 10.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 55.8 57.8 56.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -456.2 -1,598.9 -841.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 1,083.2 587.9 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -20,859.1 -42,064.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -44.5 -82.8 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -31.5 -48.5 -93.8 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.0 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -33.7 -50.5 -103.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -33.7 -50.5 -103.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 12,989.2 31,115.6 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 12,989.2 31,115.6 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A N/A 1,755.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 12,989.2 31,115.6 -1,755.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PAB Shortsell

Frequently Asked Questions

The current share price of Patrys Limited (PAB:ASX) is AU$0.008.
The 52-week high share price for Patrys Limited (PAB:ASX) is AU$0.03.
The 52-week low share price for Patrys Limited (PAB:ASX)? is AU$0.01.
Patrys Limited (PAB:ASX) does not pay a dividend.
Patrys Limited (PAB:ASX) does not pay a dividend.
Patrys Limited (PAB:ASX) has a franking level of 0%.
Patrys Limited (PAB:ASX) is classified in the Healthcare.
The current P/E ratio for Patrys Limited (PAB:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.